Honasa Consumer expects a 30% year-on-year increase in operating revenue for the quarter ending June 2026, fueled by momentum in both its flagship and emerging brands, alongside enhanced offline distribution and strategic acquisitions.
- Operating revenue expected to grow 30% YoY in Q1 FY27
- Offline distribution expands from 1.2L to 3L outlets planned
- Acquisition of Fluence Pharma marks entry into nutrition
What happened
Honasa Consumer, known for its flagship brand Mamaearth, projects a 30% year-on-year increase in its operating revenue for the quarter ending June 30, 2026 (Q1 FY27). This growth is slightly moderated on a reported basis due to new revenue recognition rules introduced by the Flipkart Group, which now deducts fulfillment and logistics costs before payment, reducing top-line figures accordingly.
Mamaearth itself is anticipated to grow in the high teens percentage-wise, supported by rising customer demand and a strengthened offline retail footprint. Honasa’s online channels continue to deliver steady gains. The company’s expansion in offline distribution, particularly through enhanced in-store execution and extended reach in general trade, has contributed to improved operating margins exceeding double digits during the quarter.
Why it matters
Honasa Consumer’s performance highlights the company’s effective multi-brand strategy and balanced growth across online and offline channels amid evolving retail dynamics. Beyond Mamaearth, other portfolio brands like Dr. Sheth’s, The Derma Co, and BBlunt increasingly contribute to overall growth, signaling diversification away from a single flagship product.
Recent acquisitions, particularly the purchase of a majority stake in nutraceutical company Fluence Pharma, mark a strategic move into the growing nutrition and supplements market. The integration of new categories and scaling up of offline presence are crucial for Honasa’s ambition to double revenue by FY31 and enhance EBITDA margins while reducing dependency on Mamaearth.
What to watch next
Investors and industry observers will be closely monitoring Honasa’s ability to execute its “Honasa 3.0” strategy, which targets expanding offline outlets from around 120,000 to over 300,000 by FY31 and building additional brands generating significant revenue streams. The performance of newly acquired businesses, especially Fluence Pharma and Reginald Men, will be key indicators of diversification success.
Additionally, the trajectory of The Derma Co as a potential ₹1,500 Cr revenue contributor and the launch of new brands expected to cross ₹500 Cr annually will be pivotal. Monitoring how Honasa manages increasing scale while maintaining margins amid competitive pressures in the Indian beauty, personal care, and wellness sectors will shape its long-term growth outlook.